Author's response to reviews

Title: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoitin-2 levels.

Authors:

Stefano Kim (stefanokim@gmail.com)
Erion Dobi (erion_dr@yahoo.com)
Marine Jary (jary.marine@yahoo.fr)
Franck Monnien (fmonnien@chu-besancon.fr)
Elsa Curtit (elsa.curtit7@wanadoo.fr)
Thierry Nguyen (tanhon@chu-besancon.fr)
Zaher Lakkis (zaher.lakkis@free.fr)
Bruno Heyd (bruno.heyd@univ-fcomte.fr)
Serge Fratte (sfratte@chbm.fr)
Denis Cleau (d.cleau@chi70.fr)
Najib Lamfichekh (nlamfichekh@chbm.fr)
Virginie Nerich (vnerich@yahoo.fr)
Boris Guiu (bguiu@hotmail.fr)
Martin Demarchi (martindemarchi@hotmail.com)
Christophe Borg (christophe.borg@efs.sante.fr)

Version: 3 Date: 9 December 2013

Author's response to reviews: see over
Editor of BMC Cancer

Christophe Borg, MD, PhD  
Immunology and cancer therapy unit  
University Hospital of Besançon  
INSERM U645  
EFS Bourgogne Franche Comté  
2 Bd Fleming  
25020 Besançon, France  
email: Christophe.borg@efs.sante.fr  
phone: 33 3 81 51 56 15  
fax: 33 3 81 61 56 17

Besançon, 8th December 2013

Dear Editorial Committee,

Thank you for having accepted for publication our manuscript written by KIM S. et al. and entitled "Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels."

As requested, the present manuscript contains the modifications required by the editorial committee.

- “Summary” was replaced by “Abstract”
- Trial registration number was included after the abstract
- Author contribution and acknowledgements were including before the references
- As stated in the title page, authors have no conflict of interest to declare.

Thank you for considering our work. Should you need any further assistance, please do not hesitate to contact me.

Best regards,

Christophe Borg M.D., PhD  
Department of Immunology and Cancer Therapy  
Unit INSERM U 1098